When to Refer and Further Autoantibody Testing

Systemic lupus erythematosus (SLE) can present at any age and is associated with immune-mediated damage to multiple organs and increased rates of cardiovascular disease, cancer, and disability. New treatments have been FDA approved. Caroline H. Siegel, MD, MS, discusses this and more with JAMA Deputy Editor Mary McGrae McDermott, MD. Related Content:

• Systemic Lupus Erythematosus